Organogenesis_Logo_Corporate_Square_yahoo.jpg
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023
February 09, 2023 07:30 ET | Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis_Logo_Corporate_Square_yahoo.jpg
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
December 05, 2022 07:30 ET | Organogenesis Holdings Inc.
CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET | Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022
September 26, 2022 09:12 ET | Organogenesis Holdings Inc.
CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022 07:30 ET | Organogenesis Holdings Inc.
CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis_Logo_Corporate.jpg
Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution
August 15, 2022 07:00 ET | Organogenesis Holdings Inc.
CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
August 09, 2022 16:05 ET | Organogenesis Holdings Inc.
CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022
June 30, 2022 07:30 ET | Organogenesis Holdings Inc.
CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis_Logo_Corporate.jpg
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET | Organogenesis Holdings Inc.
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis_Logo_Corporate.jpg
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
May 05, 2022 16:05 ET | Organogenesis Holdings Inc.
CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...